INVA insider trading
NasdaqGS HealthcareInnoviva, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Innoviva, Inc.
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline), a tetracycline class antibacterial for the treatment of complicated intra-abdominal infections in adults; XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia; and ZEVTERA, a cephalosporin antibacterial for the treatment of adult patients with staphylococcus aureus bloodstream infections, adult patients with acute bacterial skin and skin structure infections, and adult and pediatric patients with community-acquired bacterial pneumonia. Its development pipeline includes Zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Company website: www.inva.com
INVA insider activity at a glance
FilingIQ has scored 253 insider transactions for INVA since Jan 14, 2016. The most recent filing in our index is dated May 4, 2026.
Across the full history, 18 open-market purchases
and 30 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on INVA insider trades is 56.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
Politicians who have traded INVA
Frequently asked
- How many insider trades does FilingIQ track for INVA?
- FilingIQ tracks 253 Form 4 insider transactions for INVA (Innoviva, Inc.), covering filings from Jan 14, 2016 onwards. 17 of those were filed in the last 90 days.
- Are INVA insiders net buyers or net sellers?
- Across the full Form 4 history for INVA, 18 transactions (7%) were open-market purchases and 30 (12%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does INVA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is INVA in?
- Innoviva, Inc. (INVA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.72B.
Methodology & sources
Every INVA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.